{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:21:16Z","timestamp":1790457676780,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Platinum resistance constitutes one of the most recognized clinical challenges for ovarian cancer. Notably, the detection of the primary tumor-based excision repair cross-complementation group 1 (ERCC1) protein by immunohistochemistry was recently shown to be inaccurate for the prediction of platinum resistance. On the basis of the previous finding that circulating tumor cells (CTC) in the blood of ovarian cancer patients are prognostically significant, and given our hypothesis that the negative prognostic impact of CTC may arise from a cellular phenotype associated with platinum resistance, we asked whether expression of the excision repair cross-complementation group 1 (ERCC1) gene in the form of the ERCC1 transcript in CTC may be a suitable blood-based biomarker for platinum resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>The presence of CTC was analyzed by immunomagnetic CTC enrichment (n = 143 patients) targeting the epithelial epitopes epithelial cell adhesion molecule (EPCAM) (also known as GA733-2) and mucin 1, cell surface associated (MUC1), followed by multiplex reverse-transcription PCR to detect the transcripts EPCAM, MUC1, and mucin 16, cell surface associated (MUC16) (also known as CA125), including ERCC1 transcripts in a separate approach. ERCC1 expression in primary tumors was comparatively assessed by immunohistochemistry, using the antibody 8F1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>At primary diagnosis, the presence of CTC was observed in 14% of patients and constituted an independent predictor of overall survival (OS) (P = 0.041). ERCC1-positive CTC (ERCC1+CTC) were observed in 8% of patients and constituted an independent predictor, not only for OS but also for progression-free survival (PFS) (P = 0.026 and P = 0.009, respectively). More interestingly, we discovered the presence of ERCC1+CTC at primary diagnosis to be likewise an independent predictor of platinum resistance (P = 0.010), whereas ERCC1 expression in corresponding primary tumor tissue predicted neither platinum resistance nor prognosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The presence of ERCC1+CTC can serve as a blood-based diagnostic biomarker for predicting platinum resistance at primary diagnosis of ovarian cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2014.224808","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T23:19:34Z","timestamp":1405120774000},"page":"1282-1289","source":"Crossref","is-referenced-by-count":104,"title":["ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance"],"prefix":"10.1093","volume":"60","author":[{"given":"Jan Dominik","family":"Kuhlmann","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, West German Cancer Center, University Hospital of Essen, Essen, Germany"},{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wimberger","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, West German Cancer Center, University Hospital of Essen, Essen, Germany"},{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Bankfalvi","sequence":"first","affiliation":[{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"},{"name":"Department of Pathology and Neuropathology, University Hospital of Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Keller","sequence":"first","affiliation":[{"name":"Acomed Statistics, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sch\u00f6ler","sequence":"first","affiliation":[{"name":"Department of Pathology and Neuropathology, University Hospital of Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahriye","family":"Aktas","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, West German Cancer Center, University Hospital of Essen, Essen, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Buderath","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, West German Cancer Center, University Hospital of Essen, Essen, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Hauch","sequence":"first","affiliation":[{"name":"Adnagen AG, Langenhagen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Otterbach","sequence":"first","affiliation":[{"name":"Department of Pathology and Neuropathology, University Hospital of Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Kimmig","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, West German Cancer Center, University Hospital of Essen, Essen, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Kasimir-Bauer","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, West German Cancer Center, University Hospital of Essen, Essen, Germany"},{"name":"German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"key":"2020022705521687000_B1","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1002\/cncr.11349","article-title":"Incidence of ovarian cancer by race and ethnicity in the United States, 1992\u20131997","volume":"97","author":"Goodman","year":"2003","journal-title":"Cancer"},{"key":"2020022705521687000_B2","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","article-title":"2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2005","journal-title":"Ann Oncol"},{"key":"2020022705521687000_B3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"key":"2020022705521687000_B4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0009-2797(80)90122-2","article-title":"Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA","volume":"30","author":"Johnson","year":"1980","journal-title":"Chem Biol Interact"},{"key":"2020022705521687000_B5","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"2020022705521687000_B6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0092-8674(00)80155-5","article-title":"Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease","volume":"86","author":"Sijbers","year":"1996","journal-title":"Cell"},{"key":"2020022705521687000_B7","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1074\/jbc.272.6.3833","article-title":"Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex","volume":"272","author":"Bessho","year":"1997","journal-title":"J Biol Chem"},{"key":"2020022705521687000_B8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1126\/science.284.5416.958","article-title":"Action of DNA repair endonuclease ERCC1\/XPF in living cells","volume":"284","author":"Houtsmuller","year":"1999","journal-title":"Science"},{"key":"2020022705521687000_B9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/1097-0215(20000920)89:5<453::AID-IJC9>3.0.CO;2-E","article-title":"ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells","volume":"89","author":"Britten","year":"2000","journal-title":"Int J Cancer"},{"key":"2020022705521687000_B10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/tpj.2011.29","article-title":"TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials","volume":"12","author":"Grimminger","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"2020022705521687000_B11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3892\/ol.2012.1096","article-title":"The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy","volume":"5","author":"Liu","year":"2013","journal-title":"Oncol Lett"},{"key":"2020022705521687000_B12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N Engl J Med"},{"key":"2020022705521687000_B13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.dnarep.2010.03.010","article-title":"Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells","volume":"9","author":"Arora","year":"2010","journal-title":"DNA Repair"},{"key":"2020022705521687000_B14","first-page":"708","article-title":"Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian cancer patients treated with platinum-based chemotherapy","volume":"16","author":"Milovic-Kovacevic","year":"2011","journal-title":"J BUON"},{"key":"2020022705521687000_B15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2010.07.018","article-title":"Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma","volume":"119","author":"Scheil-Bertram","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2020022705521687000_B16","first-page":"86","article-title":"The protein expression of ERCC1 and survivin in epithelial ovarian carcinoma and their clinical significance","volume":"42","author":"Xie","year":"2011","journal-title":"[Chinese] Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"2020022705521687000_B17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/IGC.0b013e318218f28b","article-title":"Expression of ERCC1, p53, and class III \u03b2-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study","volume":"21","author":"Vandenput","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"2020022705521687000_B18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00428-011-1110-1","article-title":"Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy","volume":"459","author":"Bosmuller","year":"2011","journal-title":"Virchows Arch"},{"key":"2020022705521687000_B19","doi-asserted-by":"crossref","first-page":"e25164","DOI":"10.1371\/journal.pone.0025164","article-title":"Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations","volume":"6","author":"Hubner","year":"2011","journal-title":"PLoS One"},{"key":"2020022705521687000_B20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"N Engl J Med"},{"key":"2020022705521687000_B21","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/IGC.0b013e318216cb91","article-title":"Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy","volume":"21","author":"Aktas","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"2020022705521687000_B22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","article-title":"Histopathologic grading of ovarian carcinoma: a review and proposal","volume":"19","author":"Silverberg","year":"2000","journal-title":"Int J Gynecol Pathol"},{"key":"2020022705521687000_B23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2008.12.015","article-title":"FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia","volume":"105","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"2020022705521687000_B24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1373\/clinchem.2012.194258","article-title":"Circulating tumor cells: liquid biopsy of cancer","volume":"59","author":"Alix-Panabieres","year":"2013","journal-title":"Clin Chem"},{"key":"2020022705521687000_B25","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1373\/clinchem.2011.165068","article-title":"Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges","volume":"57","author":"Lianidou","year":"2011","journal-title":"Clin Chem"},{"key":"2020022705521687000_B26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"2020022705521687000_B27","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1158\/1078-0432.CCR-05-2821","article-title":"Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival","volume":"12","author":"Hayes","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2020022705521687000_B28","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020022705521687000_B29","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2020022705521687000_B30","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdr263","article-title":"High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients","volume":"23","author":"Pierga","year":"2012","journal-title":"Ann Oncol"},{"key":"2020022705521687000_B31","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1200\/JCO.2008.18.0497","article-title":"Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer","volume":"27","author":"Xenidis","year":"2009","journal-title":"J Clin Oncol"},{"key":"2020022705521687000_B32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2012.09.021","article-title":"Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance\u2014a study of the OVCAD consortium","volume":"128","author":"Obermayr","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2020022705521687000_B33","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/0008-5472.CAN-12-4140","article-title":"Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing","volume":"73","author":"Heitzer","year":"2013","journal-title":"Cancer Res"},{"key":"2020022705521687000_B34","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2005.04.5948","article-title":"Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients","volume":"24","author":"Xenidis","year":"2006","journal-title":"J Clin Oncol"},{"key":"2020022705521687000_B35","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/ijc.26111","article-title":"Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen Adna Test BreastCancer Select\/Detect versus Veridex Cellsearch system","volume":"130","author":"Andreopoulou","year":"2012","journal-title":"Int J Cancer"},{"key":"2020022705521687000_B36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.lungcan.2012.04.005","article-title":"ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy","volume":"77","author":"Das","year":"2012","journal-title":"Lung Cancer"},{"key":"2020022705521687000_B37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-011-1508-0","article-title":"Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced\/inflammatory, and stage IV breast cancer, using a novel detection technology","volume":"128","author":"Somlo","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2020022705521687000_B38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nbt.2576","article-title":"Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay","volume":"31","author":"Baccelli","year":"2013","journal-title":"Nat Biotechnol"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/60\/10\/1282\/32663273\/clinchem1282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/60\/10\/1282\/32663273\/clinchem1282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T05:53:13Z","timestamp":1582782793000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/60\/10\/1282\/5621697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,1]]},"published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2014.224808","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,10,1]]},"published":{"date-parts":[[2014,10,1]]}}}